Michael Marash, CEO of P-Cure, stated, “The integration of Proton ARC therapy into routine clinical practice underscores the versatility and innovation of P-Cure’s proton therapy system. By addressing the challenges of space, cost, and accessibility, we are democratizing proton therapy and bringing this life-saving technology to more patients worldwide. This collaboration with Hadassah exemplifies how advanced technology can align with clinical excellence to transform cancer care.”
About P-Cure
P-Cure is a leading provider of compact and innovative proton therapy solutions designed to enhance accessibility and precision in cancer treatment. With its groundbreaking technologies, P-Cure addresses the limitations of conventional systems, offering compact designs that fit into existing clinical settings without compromising treatment efficacy.
Proton therapy, including for proton active scanning therapy – the basis for ARC treatment -- is FDA-cleared for certain tumor localizations. Consult your healthcare provider for details about your specific treatment needs.
Back to HCB News
